Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemia.

Othman J, Verner E, Tam CS, Huang J, Lin L, Hilger J, Trotman J, Gasiorowski R.

Haematologica. 2018 May;103(5):e223-e225. doi: 10.3324/haematol.2017.186817. Epub 2018 Feb 8. No abstract available.

2.

COINSTAC: Decentralizing the future of brain imaging analysis.

Ming J, Verner E, Sarwate A, Kelly R, Reed C, Kahleck T, Silva R, Panta S, Turner J, Plis S, Calhoun V.

F1000Res. 2017 Aug 18;6:1512. doi: 10.12688/f1000research.12353.1. eCollection 2017.

3.

The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance.

Venetsanakos E, Brameld KA, Phan VT, Verner E, Owens TD, Xing Y, Tam D, LaStant J, Leung K, Karr DE, Hill RJ, Gerritsen ME, Goldstein DM, Funk JO, Bradshaw JM.

Mol Cancer Ther. 2017 Dec;16(12):2668-2676. doi: 10.1158/1535-7163.MCT-17-0309. Epub 2017 Oct 4.

4.

Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors.

Brameld KA, Owens TD, Verner E, Venetsanakos E, Bradshaw JM, Phan VT, Tam D, Leung K, Shu J, LaStant J, Loughhead DG, Ton T, Karr DE, Gerritsen ME, Goldstein DM, Funk JO.

J Med Chem. 2017 Aug 10;60(15):6516-6527. doi: 10.1021/acs.jmedchem.7b00360. Epub 2017 Jul 25.

PMID:
28665128
5.

Formalising multidisciplinary peer review: developing a haematological malignancy-specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence-based clinical practice.

Trotman J, Trinh J, Kwan YL, Estell JA, Fletcher J, Archer K, Lee K, Foo K, Curnow J, Bianchi A, Wignall L, Verner E, Gasiorowski R, Siedlecka E, Cunningham I.

Intern Med J. 2017 May;47(5):542-548. doi: 10.1111/imj.13302.

PMID:
27753208
6.

Delayed feedback induced multirhythmicity in the oscillatory electrodissolution of copper.

Nagy T, Verner E, Gáspár V, Kori H, Kiss IZ.

Chaos. 2015 Jun;25(6):064608. doi: 10.1063/1.4921694.

PMID:
26117133
7.

Prolonged and tunable residence time using reversible covalent kinase inhibitors.

Bradshaw JM, McFarland JM, Paavilainen VO, Bisconte A, Tam D, Phan VT, Romanov S, Finkle D, Shu J, Patel V, Ton T, Li X, Loughhead DG, Nunn PA, Karr DE, Gerritsen ME, Funk JO, Owens TD, Verner E, Brameld KA, Hill RJ, Goldstein DM, Taunton J.

Nat Chem Biol. 2015 Jul;11(7):525-31. doi: 10.1038/nchembio.1817. Epub 2015 May 25.

8.

Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.

Zhong Y, Dong S, Strattan E, Ren L, Butchar JP, Thornton K, Mishra A, Porcu P, Bradshaw JM, Bisconte A, Owens TD, Verner E, Brameld KA, Funk JO, Hill RJ, Johnson AJ, Dubovsky JA.

J Biol Chem. 2015 Mar 6;290(10):5960-78. doi: 10.1074/jbc.M114.614891. Epub 2015 Jan 15.

9.

Two rare cases of blastic plasmacytoid dendritic cell neoplasm and a literature review.

Chu G, Verner E, Lee K, Painter V, Fletcher J, Curnow J.

Leuk Lymphoma. 2014 Oct;55(10):2405-7. doi: 10.3109/10428194.2014.883074. Epub 2014 Feb 14. Review. No abstract available.

PMID:
24432892
10.
13.

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ.

Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80. doi: 10.1073/pnas.1004594107. Epub 2010 Jul 6.

14.

ADAMTS-13 activity, microangiopathic haemolytic anaemia and thrombocytopenia following snake bite envenomation.

Ho WK, Verner E, Dauer R, Duggan J.

Pathology. 2010 Feb;42(2):200-2. doi: 10.3109/00313020903493955. No abstract available.

PMID:
20085531
15.

Kepler planet-detection mission: introduction and first results.

Borucki WJ, Koch D, Basri G, Batalha N, Brown T, Caldwell D, Caldwell J, Christensen-Dalsgaard J, Cochran WD, DeVore E, Dunham EW, Dupree AK, Gautier TN 3rd, Geary JC, Gilliland R, Gould A, Howell SB, Jenkins JM, Kondo Y, Latham DW, Marcy GW, Meibom S, Kjeldsen H, Lissauer JJ, Monet DG, Morrison D, Sasselov D, Tarter J, Boss A, Brownlee D, Owen T, Buzasi D, Charbonneau D, Doyle L, Fortney J, Ford EB, Holman MJ, Seager S, Steffen JH, Welsh WF, Rowe J, Anderson H, Buchhave L, Ciardi D, Walkowicz L, Sherry W, Horch E, Isaacson H, Everett ME, Fischer D, Torres G, Johnson JA, Endl M, MacQueen P, Bryson ST, Dotson J, Haas M, Kolodziejczak J, Van Cleve J, Chandrasekaran H, Twicken JD, Quintana EV, Clarke BD, Allen C, Li J, Wu H, Tenenbaum P, Verner E, Bruhweiler F, Barnes J, Prsa A.

Science. 2010 Feb 19;327(5968):977-80. doi: 10.1126/science.1185402. Epub 2010 Jan 7.

16.

Isoform-specific histone deacetylase inhibitors: the next step?

Balasubramanian S, Verner E, Buggy JJ.

Cancer Lett. 2009 Aug 8;280(2):211-21. doi: 10.1016/j.canlet.2009.02.013. Epub 2009 Mar 16. Review.

PMID:
19289255
17.

A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas.

Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ.

Leukemia. 2008 May;22(5):1026-34. doi: 10.1038/leu.2008.9. Epub 2008 Feb 7.

PMID:
18256683
18.

CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo.

Cao ZA, Bass KE, Balasubramanian S, Liu L, Schultz B, Verner E, Dai Y, Molina RA, Davis JR, Misialek S, Sendzik M, Orr CJ, Leung L, Callan O, Young P, Dalrymple SA, Buggy JJ.

Mol Cancer Ther. 2006 Jul;5(7):1693-701.

19.

CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo.

Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, Liu L, Schultz BE, Young PR, Dalrymple SA.

Mol Cancer Ther. 2006 May;5(5):1309-17.

20.

Generation of potent coagulation protease inhibitors utilizing zinc-mediated chelation.

Young WB, Sprengeler P, Shrader WD, Li Y, Rai R, Verner E, Jenkins T, Fatheree P, Kolesnikov A, Janc JW, Cregar L, Elrod K, Katz B.

Bioorg Med Chem Lett. 2006 Feb;16(3):710-3. Epub 2005 Oct 27.

PMID:
16257204
21.

Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).

Katz BA, Luong C, Ho JD, Somoza JR, Gjerstad E, Tang J, Williams SR, Verner E, Mackman RL, Young WB, Sprengeler PA, Chan H, Mortara K, Janc JW, McGrath ME.

J Mol Biol. 2004 Nov 19;344(2):527-47.

PMID:
15522303
22.

Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases.

Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ, Luong C, Arvai A, Buggy JJ, Chi E, Tang J, Sang BC, Verner E, Wynands R, Leahy EM, Dougan DR, Snell G, Navre M, Knuth MW, Swanson RV, McRee DE, Tari LW.

Structure. 2004 Jul;12(7):1325-34.

23.

Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors.

Katz BA, Elrod K, Verner E, Mackman RL, Luong C, Shrader WD, Sendzik M, Spencer JR, Sprengeler PA, Kolesnikov A, Tai VW, Hui HC, Breitenbucher JG, Allen D, Janc JW.

J Mol Biol. 2003 May 23;329(1):93-120.

PMID:
12742021
24.

2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors.

Mackman RL, Hui HC, Breitenbucher JG, Katz BA, Luong C, Martelli A, McGee D, Radika K, Sendzik M, Spencer JR, Sprengeler PA, Tario J, Verner E, Wang J.

Bioorg Med Chem Lett. 2002 Aug 5;12(15):2019-22.

PMID:
12113832
25.

Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.

Katz BA, Sprengeler PA, Luong C, Verner E, Elrod K, Kirtley M, Janc J, Spencer JR, Breitenbucher JG, Hui H, McGee D, Allen D, Martelli A, Mackman RL.

Chem Biol. 2001 Nov;8(11):1107-21.

26.

Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator.

Mackman RL, Katz BA, Breitenbucher JG, Hui HC, Verner E, Luong C, Liu L, Sprengeler PA.

J Med Chem. 2001 Nov 8;44(23):3856-71.

PMID:
11689072
27.

Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa.

Verner E, Katz BA, Spencer JR, Allen D, Hataye J, Hruzewicz W, Hui HC, Kolesnikov A, Li Y, Luong C, Martelli A, Radika K, Rai R, She M, Shrader W, Sprengeler PA, Trapp S, Wang J, Young WB, Mackman RL.

J Med Chem. 2001 Aug 16;44(17):2753-71.

PMID:
11495587
28.

Development of potent and selective factor Xa inhibitors.

Rai R, Kolesnikov A, Li Y, Young WB, Leahy E, Sprengeler PA, Verner E, Shrader WD, Burgess-Henry J, Sangalang JC, Allen D, Chen X, Katz BA, Luong C, Elrod K, Cregar L.

Bioorg Med Chem Lett. 2001 Jul 23;11(14):1797-800.

PMID:
11459634
29.

A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.

Katz BA, Elrod K, Luong C, Rice MJ, Mackman RL, Sprengeler PA, Spencer J, Hataye J, Janc J, Link J, Litvak J, Rai R, Rice K, Sideris S, Verner E, Young W.

J Mol Biol. 2001 Apr 13;307(5):1451-86.

PMID:
11292354
30.

The discovery and structure-activity relationships of nonpeptide, low molecular weight antagonists selective for the endothelin ET(B) receptor.

Chan MF, Kois A, Verner EJ, Raju BG, Castillo RS, Wu C, Okun I, Stavros FD, Balaji VN.

Bioorg Med Chem. 1998 Dec;6(12):2301-16.

PMID:
9925292
31.

Skin-isolated, community-acquired Staphylococcus aureus: in vitro resistance to methicillin and erythromycin.

Ohana N, Keness J, Verner E, Raz R, Rozenman D, Zuckerman F.

J Am Acad Dermatol. 1989 Sep;21(3 Pt 1):544-6.

PMID:
2789236
32.

Diagnostic and therapeutic approach to Ethiopian immigrants seropositive for syphilis.

Verner E, Shteinfeld M, Raz R, Sofer N, Sartiel J, Sandbank J, Zuckerman F.

Isr J Med Sci. 1988 Mar;24(3):151-5.

PMID:
3372222
33.

[Norwegian scabies in a psoriatic mental patient].

Verner E, Shteinfeld M, Zuckerman F.

Harefuah. 1987 Apr 1;112(7):328-31. Hebrew. No abstract available.

PMID:
3623293
34.

[Cutaneous leishmaniasis in Ethiopian immigrants in Israel].

Verner E, el-On J, Oren J, Zuckerman F.

Harefuah. 1986 Dec 15;111(12):416-8. Hebrew. No abstract available.

PMID:
3557211
35.

[New therapeutic approach in treatment in early latent and asymptomatic neurosyphilis].

Verner E.

Harefuah. 1986 Dec 15;111(12):441-3. Review. Hebrew. No abstract available.

PMID:
3549482
36.

[Tinea capitis in Nazareth].

Verner E, Bisharat B, Mendelovitz S, Zuckerman F.

Harefuah. 1986 Nov 2;111(9):226-8. Hebrew. No abstract available.

PMID:
3817638
37.

Zollinger-Ellison syndrome associated with a renal gastrinoma in a child.

Nord KS, Joshi V, Hanna M, Khademi M, Saad S, Marquis J, Pelzman H, Verner E.

J Pediatr Gastroenterol Nutr. 1986 Nov-Dec;5(6):980-6.

PMID:
2878987
38.

Failure of oral ketoconazole to cure cutaneous ulcers caused by Leishmania braziliensis.

Dan M, Verner E, el-On J, Zuckerman F, Michaeli D.

Cutis. 1986 Sep;38(3):198-9.

PMID:
3769557
39.

[Pustular psoriasis during maintenance treatment with etretinate].

Verner E, Rosenman D.

Harefuah. 1986 Feb 2;110(3):132-3. Hebrew. No abstract available.

PMID:
2940160
40.

Eczema herpeticum in a patient with Darier's disease during treatment with etretinate.

Verner E, Shteinfeld M, Zuckerman F.

J Am Acad Dermatol. 1985 Oct;13(4):678-80. No abstract available.

PMID:
4078062
41.

Spinal epidural abscess.

Verner EF, Musher DM.

Med Clin North Am. 1985 Mar;69(2):375-84.

PMID:
3990440
42.

[Leishmania brasiliensis infection].

Verner E, Zuckerman F.

Harefuah. 1985 Feb 15;108(4):185-6. Hebrew. No abstract available.

PMID:
4007665
43.
45.

Mammary gland topography, a new clinical approach in the early diagnosis of breast cancer. Preliminary report.

Verner EW.

J Med Soc N J. 1968 Feb;65(2):50-6. No abstract available.

PMID:
5236089
46.

Chondrosarcoma of the extraskeletal soft tissues.

STOUT AP, VERNER EW.

Cancer. 1953 May;6(3):581-90. No abstract available.

PMID:
13042781

Supplemental Content

Loading ...
Support Center